Zura Bio Appoints Sandeep Kulkarni as CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Zura Bio announced the appointment of Sandeep Kulkarni as CEO, effective January 21. Kulkarni will also continue serving as a director of Zura. Kulkarni succeeds Kim Davis, who has served as interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Lisicki is resigning as CEO and as a director, effective as of January 21. Davis will continue in her roles as chief operating officer, chief legal officer, and corporate secretary. Most recently, Kulkarni served as co-founder and CEO of Tourmaline Bio.
Analyst Views on ZURA
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 16.50 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.380
Low
15.00
Averages
16.50
High
18.00
Current: 6.380
Low
15.00
Averages
16.50
High
18.00
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








